共 58 条
[31]
Motzer RJ(2021)Open-Label, single-arm phase II study of Pembrolizumab Monotherapy as First-Line therapy in patients with Advanced Clear Cell Renal Cell Carcinoma J Clin Oncol 39 1020-88
[32]
Motzer TK(2021)Open-Label, Single-Arm, phase II study of Pembrolizumab Monotherapy as First-Line therapy in patients with Advanced Non-clear Cell Renal Cell Carcinoma J Clin Oncol 39 1029-5
[33]
Choueiri R(2012)The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 12 252-8
[34]
Motzer RJ(2017)PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: mechanism, combinations, and clinical outcome Front Pharmacol 8 561-7
[35]
Motzer C-H(2015)Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer Drugs Today (Barc) 51 7-undefined
[36]
Lee DF(2016)Management of adverse events following treatment with Anti-programmed Death-1 agents Oncologist 21 1230-undefined
[37]
McDermott DF(2022)Pembrolizumab-Induced Acute skin reaction: a Case Report and Review of Literature Cureus 14 e26143-undefined
[38]
McDermott DM(2020)Neurologic complications of immune checkpoint inhibitors Expert Opin Drug Saf 19 479-undefined
[39]
Pardoll HO(2022)Pembrolizumab-Induced Myasthenia gravis and myositis: Literature Review on neurological toxicities of programmed death protein 1 inhibitors J Med Cases 13 530-undefined
[40]
Alsaab J(2019)Immunotherapy-induced endocrinopathies: assessment, management and monitoring Ther Adv Endocrinol Metab 10 2042018819896182-undefined